Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Webcast: EDAP Presentation at Roth Capital Conference
Webcast: EDAP Presentation at Roth Capital Conference EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, presented at the Roth Capital Partners New York Conference on September 6, 2006 at the Westin Time Square Hotel in New
View HTML
Toggle Summary EDAP TMS S.A. to Present at Roth Capital Conference in New York
EDAP TMS S.A. to Present at Roth Capital Conference in New York Lyon, France, August 24, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced management will present at the Roth Capital Partners New York
View HTML
Toggle Summary EDAP TMS S.A. Reports 2006 Second Quarter Results
HIFU Utilization Increasing as Company Accelerates Its Growth Program Company Adding Resources to Launch RPP Centers More Quickly
View HTML
Toggle Summary EDAP TMS S.A. Closes Private Placement
Proceeds to Enhance Marketing to Accelerate Ablatherm-HIFU RPP Business in Europe
View HTML
Toggle Summary EDAP TMS S.A. to Release 2006 Second Quarter Financial Results August 8, 2006
EDAP TMS S.A. to Release 2006 Second Quarter Financial Results August 8, 2006 Lyon, France, August 3, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , will release its second quarter financial results for the period ending June 30, 2006 on Tuesday, August 8, 2006 after the market close.
View HTML
Toggle Summary Third Mobile Ablatherm-HIFU Device to Start Service in Germany; Ongoing Growth
Increasing Sites and Utilization Rate Necessitates Third Unit; Market More Than Double Prior Year
View HTML
Toggle Summary Ablatherm-HIFU Launches RPP Service at First Site in Portugal
New Site to Launch Fixed RPP Services Model; First Portuguese HIFU Center
View HTML
Toggle Summary Ablatherm-HIFU experience highlighted by UK Prostate Cancer Charity
Ablatherm-HIFU experience highlighted by UK Prostate Cancer Charity The Prostate Cancer Charity , the largest and most comprehensive charity in the UK focused on prostate cancer, recently included a 4-page detailed overview of HIFU treatment for localized prostate cancer in its widely distributed
View HTML
Toggle Summary Ablatherm FDA Study in Triangle Business Journal
Ablatherm FDA Study in Triangle Business Journal EDAP's Ablatherm-HIFU FDA clinical study was recently featured in the Triangle Business Journal. The article is viewable online at http://triangle.bizjournals.com/triangle/stories/2006/07/17/focus4.html  .  A patient treated at Duke University
View HTML
Toggle Summary EDAP TMS S.A. Announces $7.5 Million Placement
EDAP TMS S.A. Announces $7.5 Million Placement Lyon, France, July 27, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) announced that it has entered into a securities purchase agreement with selected accredited investors pursuant to which an aggregate of 961,676 of the company's ordinary shares in the form of
View HTML